期刊
BRAIN PATHOLOGY
卷 28, 期 5, 页码 723-734出版社
WILEY
DOI: 10.1111/bpa.12641
关键词
multiple sclerosis; clinical progression; disability worsening; positron emission tomography; remyelination; innate immune cell; microglia; white matter lesions
资金
- Fondation ARSEP
- ANR (Agence Nationale de la Recherche) [MNP2008-007125]
- INSERM-DHOS
- JNLF (Journees de Neurologie de Langue Francaise)
- FRM (Fondation pour la Recherche Medicale)
- APHP (Assistance Publique des Hopitaux de Paris)
- ECTRIMS
- ELA (European Leukodystrophy Association)
- PHRC 2010 (Programme Hospitalier de Recherche Clinique)
The biological mechanisms driving disability worsening in multiple sclerosis (MS) are only partly understood. Monitoring changes in lesion load on MRI has a limited predictive value on the progression of clinical disability, and there is an essential need for novel imaging markers specific for the main candidate mechanisms underlying neurodegeneration which include failing myelin repair, innate immune cell activation and gray matter neuronal damage. Positron Emission Tomography (PET) is an imaging technology based on the injection of radiotracers directed against specific molecular targets, which has recently allowed the selective quantification in-vivo of the key biological mechanisms relevant to MS pathophysiology. Pilot PET studies performed in patients with all forms of MS allowed to revisit the contribution of MS lesions to disability worsening and showed that the evolution of lesions toward chronic activation, together with their remyelination profile were relevant predictors of disability worsening. PET offers the opportunity to bridge a critical gap between neuropathology and in-vivo imaging. This technique provides an original approach to disentangle some of the most relevant pathological components driving MS progression, to follow-up their temporal evolution, to investigate their clinical relevance and to evaluate novel therapeutics aimed to prevent disease progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据